To include your compound in the COVID-19 Resource Center, submit it here.

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites
In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing KN046 had

Read the full 364 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE